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Abstract
Backgrounds: Previous studies have shown that diffusion-weighted cardiovascular magnetic resonance (DW-CMR)
is highly sensitive to replacement fibrosis of chronic myocardial infarction. Despite this sensitivity to myocardial
infarction, DW-CMR has not been established as a method to detect diffuse myocardial fibrosis. We propose the
application of a recently developed DW-CMR technique to detect diffuse myocardial fibrosis in hypertrophic
cardiomyopathy (HCM) patients and compare its performance with established CMR techniques.
Methods: HCM patients (N = 23) were recruited and scanned with the following protocol: standard morphological
localizers, DW-CMR, extracellular volume (ECV) CMR, and late gadolinium enhanced (LGE) imaging for reference. Apparent
diffusion coefficient (ADC) and ECV maps were segmented into 6 American Heart Association (AHA) segments. Positive
regions for myocardial fibrosis were defined as: ADC > 2.0 μm2/ms and ECV > 30 %. Fibrotic and non-fibrotic mean ADC
and ECV values were compared as well as ADC-derived and ECV-derived fibrosis burden. In addition, fibrosis regional
detection was compared between ADC and ECV calculating sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) using ECV as the gold-standard reference.
Results: ADC (2.4 ± 0.2 μm2/ms) of fibrotic regions (ADC > 2.0 μm2/ms) was significantly (p < 0.01) higher than ADC (1.5
± 0.2 μm2/ms) of non-fibrotic regions. Similarly, ECV (35 ± 4 %) of fibrotic regions (ECV > 30 %) was significantly (p < 0.01)
higher than ECV (26 ± 2 %) of non-fibrotic regions. In fibrotic regions defined by ECV, ADC (2.2 ± 0.3 μm2/ms) was again
significantly (p < 0.05) higher than ADC (1.6 ± 0.3 μm2/ms) of non-fibrotic regions. In fibrotic regions defined by ADC
criterion, ECV (34 ± 5 %) was significantly (p < 0.01) higher than ECV (28 ± 3 %) in non-fibrotic regions. ADC-derived and
ECV-derived fibrosis burdens were in substantial agreement (intra-class correlation = 0.83). Regional detection between
ADC and ECV of diffuse fibrosis yielded substantial agreement (κ = 0.66) with high sensitivity, specificity, PPV, NPV, and
accuracy (0.80, 0.85, 0.81, 0.85, and 0.83, respectively).
Conclusion: DW-CMR is sensitive to diffuse myocardial fibrosis and is capable of characterizing the extent of fibrosis in
HCM patients.
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Backgrounds
Detecting and characterizing interstitial diffuse myocardial
fibrosis has significant prognostic value for cardiovascular
disease patients [1–3]. Current cardiovascular magnetic
resonance (CMR) methods to characterize diffuse myocar-
dial fibrosis include late gadolinium enhanced imaging
(LGE) [3, 4], post contrast T1 mapping [5–7], and extracel-
lular volume (ECV) mapping [7–9]. The latter two tech-
niques provide quantitative measures (T1 and ECV values)
that can further characterize the degree of fibrosis. How-
ever, these conventional techniques require the use of con-
trast and are contraindicative in patients with renal
insufficiency. Contrast-free quantitative CMR techniques
such as native T1 mapping [10], diffusion imaging [11–13],
T1ρ imaging [14], and Creatine chemical-exchange im-
aging [15] have shown promise in detecting replacement
myocardial fibrosis (i.e. scar) in chronic myocardial infarc-
tion (MI). Of these techniques, native T1 mapping [16] and
diffusion imaging [17, 18] have demonstrated additional
sensitivity to diffuse myocardial fibrosis.
Currently, in vivo diffusion tensor CMR (DT-CMR) has
been shown to be sensitive to the presence of myocyte dis-
array [19] and abnormal myocardial sheetlet mechanics
[20] in hypertrophic cardiomyopathy (HCM). However,
simple in vivo diffusion-weighted CMR (DW-CMR), which
requires less than half the measurements of DT-CMR, may
also have potential in identifying diffuse myocardial fibrosis
in HCM. Pop, et al. and Abdullah, et al. demonstrated with
histological validation that ex vivo DW-CMR has the ability
to characterize the border-zone fibrosis region of chronic
MI scar [14] and diffuse myocardial fibrosis in failing hearts
[18], respectively. DW-CMR was able to not only detect
diffuse interstitial fibrosis, but also quantify the degree of
fibrosis showing strong correlation between apparent diffu-
sion coefficient (ADC) and the percent fibrosis. In both
studies, the minimum amount of fibrosis to cause a signifi-
cant change in ADC was 20 % of fibrosis.
Therefore, it is expected that in vivo estimates of ADC
should also be sensitive to both diffuse and replacement
myocardial fibrosis if a sufficient amount of fibrosis is
present (≥20 %).We propose the application of a recently
developed DW-CMR technique [21] to detect myocardial
fibrosis in HCM patients and compare its performance
with histologically validated in-vivo contrast-enhanced
CMR techniques such as ECV and LGE.
Methods
Patient recruitment
All patients (N = 23) gave informed consent to the proto-
col, which was approved by Institutional Review Board of
Fuwai Hospital. The HCM was diagnosed (or confirmed)
by the presence of a non-dilated and hypertrophied LV on
echocardiography or CMR (maximal wall thickness
≥15 mm in adult index patients or ≥13 mm in adult
relatives of HCM patients) in the absence of another dis-
ease that could account for the hypertrophy [22]. Patients
who were known to have coronary artery disease, aortic
stenosis, amyloidosis, systemic hypertension, or contrain-
dications to CMR imaging were not included. Patients
with previous septal ablation or myectomy were excluded.
Among the 23 patients, 19 are asymmentrical type includ-
ing 14 obstructive HCM and 5 non-obstructive HCM, the
remaining 4 are apical HCM. Regarding to the LV func-
tional parameters, the mean maximal wall thickness, LV
mass, LVEF, diastolic and systolic volumes are 22.8 ±
7.6 mm, 130 ± 52 g, 65.4 ± 69 %, 66.2 ± 16.1 ml/m^2 and
23.1 ± 7.5 ml/m^2, respectively. Patient characteristics are
displayed in Table 1.
MRI protocol
All patients were scanned on at 1.5 T clinical scanner
(MAGNETOM Avanto, Siemens Healthcare, Erlangen,
Germany) with the following protocol: standard mor-
phological localizers, CINE, DW-CMR (one b0 image,
three orthogonal diffusion directions, b = 350 s/mm^2,
second order motion compensation diffusion-prepared
bSSFP) [21], ECV-CMR (pre/post contrast T1 mapping
modified look locker imaging) [8, 9], and LGE (Table 2).
Diffusion encoding of the DW-CMR was played out dur-
ing the most quiescent period of the cardiac cycle identi-
fied by standard CINE imaging (typically end systole or
end diastole) and the exhalation respiratory phase to
match ECV-CMR and LGE breath-hold positions. From
previous CINE imaging of 3 HCM patients, we deter-
mined that the quiescent period duration ranged from
50 to 80 ms. Therefore, we tailored the DW-CMR se-
quence to have a shorter diffusion preparation time
(TEprep = 80 ms) compared with the diffusion prepar-
ation time used in healthy volunteers (TEprep = 115 ms)
[21]. This also increased SNR by 2-fold to offset the loss
in singal-to-noise ratio of reducing slice thickness from
10 mm to 8 mm to match DW-CMR with ECV-CMR
and LGE. ECV-CMR and LGE were always acquired
during end diastole. DW-CMR was acquired at four
contiguous short-axis slices centered about the mid LV
due to its 3D acquisition. For ECV-CMR and LGE with
Table 1 HCM Patient Characteristics
Patients (n = 23)
Ages(years, mean ± SD) 50.0 ± 17.5(29,59)
Gender (male/female) 14/9
Body mass index(kg/m2) 22.3 ± 2.8
Systolic Blood pressure(mmHg) 114 ± 12
Systolic Blood pressure (mmHg) 78 ± 9
Family History of HCM(n, %) 8(34.8)
Data presented are n (%) for categorical variables and median ± standard
deviation for continuous variables
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2D acquisition, three short-axis slices (base, mid, and apex)
were acquired. Because of the large LV mass of HCM pa-
tients (typically 10 cm long-axis length), only the mid short
axis slice was consistently matched across all scans.
Image analysis
ADC maps were calculated for each of the three diffusion
directions (ADCx, ADCy, ADCz) using a 2-point fit to solve
a mono exponential diffusion decay in Matlab (Mathworks,
Natick, MA). A final trace apparent diffusion coefficient
(ADC) map was calculated (ADC= [ADCx +ADCy +
ADCz] / 3). ECV maps were calculated online using pre/
post T1 maps derived from a standard motion-corrected
T1 fitting technique [9] and collected hematocrit.
For quantitative regional detection and estimation of
fibrosis burden, ADC and ECV maps were segmented
into 6 American Heart Association (AHA) segments.
Positive regions for myocardial fibrosis were defined as:
mean ADC > 2.0 μm2/ms [12] and mean ECV > 30 % [9].
Fibrosis burden was defined as the number of positive
segments over the total number of segments.
Two-sample t-tests were performed to test for signifi-
cance between mean values of fibrotic and non-fibrotic
regions for ADC and ECV. Significance was denoted as
p < 0.05 and the calculations were performed in Matlab.
To statistically test for agreement in regional detection,
Cohen’s Kappa tests were performed along with calculat-
ing sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV) using ECV as the
gold-standard reference. A Bonferroni correction was per-
formed manually to the significant difference testing of re-
gional detection scores by lowering the significance limit
to p < 0.002. For fibrosis burden, Bland-Altman analysis
[23] and intra-class correlation (ICC) [24] was performed
to test for correspondence and agreement.
Results
Qualitatively, all three ADC, ECV, and LGE were concord-
ant in displaying patch-like presentation of myocardial
fibrosis (Fig. 1). Patch-like presentation of myocardial
fibrosis accounted for about 50 % (33/60) of the total
number of positive fibrosis segments found on ECV. For
diffuse presentations of myocardial fibrosis, ADC and
ECV maps demonstrated qualitatively closer visual agree-
ment. LGE required appropriate window-leveling to deter-
mine the presence of diffuse myocardial fibrosis, in which
remote slices without hyperintensity must be identified
Table 2 CMR Parameters
Diffusion CMR ECV CMR LGE CMR
Spatial Resolution 1.6 × 1.6 ×
8 mm3
2.1 × 1.9 ×
6 mm3
1.5 × 1.5 ×
6 mm3
TR 4.1 ms 2.4 ms 3.3 ms
TE 2.0 ms 1.1 ms 1.4 ms
Flip Angle 110° 35° 25°
Shots 4 1 6
Magnetization Prep
Timing
TEprep = 80 ms TImin = 110 ms TI = 300 ms
TIincrement = 80 ms
Respiratory Mode Free Breathing Breath Hold Breath Hold
Scan Time 5 to 7 min 6 min 6 min
Fig. 1 Representative examples of patch-like and diffuse representations of myocardial fibrosis in ADC, ECV, and LGE images. Although not used for
quantitative analysis, LGE is provided for visual context. Regional patches of myocardial fibrosis (white arrow) are visualized as a hyperintense region in
ADC, ECV, and LGE images. Diffuse presentation of myocardial fibrosis is qualitatively more conspicuous for both ADC and ECV image with “pepper-like”
hyper intensity texture. Note that for the LGE image, appropriate window-leveling is required to properly visualize the same “pepper-like” hyper intensity
F1
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(e.g. basal short-axis slices far from apical presentations of
diffuse myocardial fibrosis).
Quantitatively, ADC (2.4 ± 0.2 μm2/ms) of fibrotic re-
gions (ADC > 2.0 μm2/ms) was significantly (p < 0.01)
higher than ADC (1.5 ± 0.2 μm2/ms) of non-fibrotic re-
gions (Figs. 2 and 3). Similarly, ECV (35 ± 4 %) of fi-
brotic regions (ECV > 30 %) was significantly (p < 0.01)
higher than ECV (26 ± 2 %) of non-fibrotic regions. In fi-
brotic regions defined by ECV, ADC (2.2 ± 0.3 μm2/ms)
was again significantly (p < 0.05) higher than ADC (1.6 ±
0.3 μm2/ms) of non-fibrotic regions. In fibrotic regions de-
fined by ADC criterion, ECV (34 ± 5 %) was significantly
(p < 0.01) higher than ECV (28 ± 3 %) in non-fibrotic re-
gions. Excellent inter-class (Pearson) correlation (R2 = 0.72)
between ECV and ADC was observed (Fig. 4). ADC-
derived and ECV-derived fibrosis burdens were in substan-
tial agreement (ICC = 0.83) and qualitatively did not yield
any systematic biases (mean bias = 1.4 %) (Fig. 5).
Regional detection (Table 3) between ADC and ECV of
diffuse fibrosis yielded substantial agreement (κ = 0.66) with
high sensitivity, specificity, PPV, NPV, and accuracy (0.80,
0.85, 0.81, 0.85, and 0.83, respectively). About 83 % (115/
138) of the number of segments was in agreement. A vast
majority (18/23 = 78 %) of the discordant segments in-
cluded detection of large fibrotic regions that straddled the
border between two segmental zones (e.g. anterolateral and
anterior segments). The other 5 discordant segments
(Fig. 6) demonstrated unique differences between ECV and
ADC with hyperintense regions being present in one and
completely absent in the other.
Discussion
ADC was capable of detecting both patch-like and diffuse
presentation of myocardial fibrosis agreeing closely with
ECV. ADC was significantly higher in fibrotic defined by
ECV (ECV >30 %) with ECV also being significantly higher
in fibrotic regions defined by ADC (ADC > 2.0 μm2/ms).
ADC was also strongly correlated (R2 = 0.72) with ECV
yielding the possibility of quantifying the degree of fibrosis.
Fibrosis burdens derived from ECV and ADC were sub-
stantially in agreement with minimal mean bias. Regional
detection analysis demonstrated that ADC yielded
substantial agreement with ECV with high sensitivity, spe-
cificity, PPV, NPV, and accuracy.
The vast majority (18/23 = 78 %) of differences be-
tween ECV and ADC in the regional fibrosis detection
analysis were most likely due to cardiac phase mis-
match since these discordant segments encompassed
Fig. 2 Representative example of processed ADC and ECV maps with
associated AHA wheels including manual LV segmentation (top row)
and AHA wheels (bottom row). Qualitatively, the ADC and ECV are in
agreement with matching endocardial presentation of fibrosis in the
anterior and anteriolateral AHA segments. This is further substantiated
quantitatively with excellent agreement in the AHA wheels
Fig. 3 ADC and ECV in fibrosis and non-fibrosis regions defined by either ADC >2 μm2/ms or ECV > 30 % were compared. Both ADC and ECV
were significantly (p < 0.01) higher in fibrosis than non-fibrosis regions for both criteria
F2
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large (≥2 segments) fibrotic regions that were on the
border of two or more segments. ECV and ADC maps ac-
quired for these cases were in completely different cardiac
phases (end diastole vs end systole). Although infrequent
(5/138 = 4 %) in regard to the total number of segments
analyzed, the other discordant segments (5/23 = 22 %)
suggest an inherent difference between ECV and ADC.
Several possibilities could account for these few differ-
ences including the presence of unaccounted non-fibrotic
tissue that could affect ECV but not ADC, the presence of
higher order motion that cannot be fully compensated af-
fecting ADC but not ECV [12], or the potential regional
heterogeneity related to proximity to the receiver coil af-
fecting ADC more than ECV due to low signal-to-noise
ratio [25]. Further investigation is needed to pinpoint the
exact source of these potentially inherent differences be-
tween ADC and ECV.
Clinically, this study demonstrated the potential for
DW-CMR as a contrast-free alternative to LGE and
ECV for myocardial fibrosis detection. Extending previ-
ous work that identified DW-CMR’s ability to detect
replacement fibrosis [12, 17, 18], the presented work
demonstrated an additional sensitivity to diffuse presen-
tations of myocardial fibrosis when compared to ECV
and LGE. Although not rigorously tested in this study,
our preliminary application of DW-CMR in HCM pa-
tients and previous study in chronic MI porcine [12]
suggest that differentiating between diffuse and replace-
ment fibrosis using DW-CMR is possible. DW-CMR is
similar to ECV and LGE in its ability to differentiate
between diffuse and replacement fibrosis by means of
examining the qualitative presentation of a quantita-
tively observed elevated (>2 um2/ms) region. If the
observed elevated region is focal in presentation and
has a higher ADC value than other suspected elevated
regions, then the observed region is more likely replace-
ment fibrosis. However, further rigorous studies are
needed to be more quantitative and exact in differentiat-
ing between replacement and diffuse fibrosis using DW-
CMR. Additionally, DW-CMR has also demonstrated
clinical potential in detecting edema in acute myocardi-
tis [26].
Practically, DW-CMR requires more robustness in order
for it to feasibly be an effective LGE or ECV contrast-free
alternative used in a clinical setting. The DW-CMR tech-
nique in this study relied on manually finding the most qui-
escent period to trigger the motion compensated diffusion
preparation. About half the patients required end systolic
triggering due to high and unstable heart rates that greatly
shortened the duration of end diastole and/or inconsistent
triggering. Automatic or semi-automatic methods in
Fig. 4 Correlation between mean ADC and ECV of the 138 AHA
segments was substantial (R2 = 0.72). ADC and ECV ranged from
0.7 to 2.9 μm2/ms and 16 to 46 %, respectively
Fig. 5 Bland-Altman plot of ADC-derived fibrosis burden compared with
ECV-derived fibrosis burden. Qualitatively, no systematic bias errors were
observed. The ICC demonstrated strong agreement (0.85) and mean bias
was minimal (1.4 %)
Table 3 Fibrosis Detection ADC vs ECV
ECV
+ -
ADC + 49 12
- 11 66
# of segments in agreement 115 (83 %)
Cohen’s Kappa (κ) 0.66*
Paired t-test test (p) NS
# of ADC fibrosis segments 60 (44 %)







aECV was gold standard
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determining the ideal cardiac phase to trigger would make
this technique more feasibly push-button. Another major
practical limitation of the DW-CMR approach used in this
study was the low spatial coverage (4 slices at 8 mm thick-
ness = 32 mm coverage) given the limited 5 min clinical
scan time. In principle, this DW-CMR approach could
achieve whole LV coverage (~80 mm) but would require at
least 12.5 min of scan time. Specifically for HCM patients
with larger LV masses, the minimum required scan time
would need to be closer to 15 min to sufficiently cover the
whole LV (~100 mm). As a result, this technical limitation
restricted the overall study design, in which estimation
of whole LV fibrosis burden could not be assessed. One
possible future technical solution is the potential coup-
ling of the motion compensated diffusion preparation
with a time-efficient hybrid radial-Cartesian segmented
3D readout [27].
Conclusion
DW-CMR is a contrast-free non-invasive quantitative tech-
nique that is sensitive to diffuse presentations of myocardial
fibrosis in HCM patients. When compared to the estab-
lished contrast-enhanced ECV-CMR, DW-CMR is able to
yield comparable detection and characterization of myocar-
dial fibrosis.
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